The Report
Verified funding, headquarters, and leadership news from the world's most innovative businesses
7,612 reports and counting
BioNTech raises $325M Follow-on Offering at $45B valuation
BioNTech raises $325M in Follow-on Offering at $45B valuation. Immunotherapy and mRNA vaccines...
Editas Medicine raises $118M Follow-on Offering at $1.8B valuation
Editas Medicine raises $118M in Follow-on Offering at $1.8B valuation. Genome editing medicines...
Intellia Therapeutics raises $350M Follow-on Offering at $4.5B valuation
Intellia Therapeutics raises $350M in Follow-on Offering at $4.5B valuation. In vivo CRISPR gene editing...
CRISPR Therapeutics raises $337M Follow-on Offering at $8B valuation
CRISPR Therapeutics raises $337M in Follow-on Offering at $8B valuation. Gene-based medicines using CRISPR/Cas9...
BioNTech Raises $325M in Follow-on Offering
BioNTech, a Biotech company based in An der Goldgrube 12, Mainz 55131, Germany, has raised $325M in Follow-on Offering at a $45B valuation led by Strüngmann Family Office, MIG, Salvia, AT Impf, Pfizer.
CRISPR Therapeutics Raises $337M in Follow-on Offering
CRISPR Therapeutics, a Biotech company based in Aeschenvorstadt 36, Basel 4051, Switzerland, has raised $337M in Follow-on Offering at a $8B valuation led by Versant Ventures, Bayer, Vertex Pharmaceuticals.
Editas Medicine Raises $118M in Follow-on Offering
Editas Medicine, a Biotech company based in 11 Hurley Street, Cambridge, MA 02141, has raised $118M in Follow-on Offering at a $1.8B valuation led by Polaris Partners, Flagship Pioneering, Third Rock Ventures, Google Ventures.
Intellia Therapeutics Raises $350M in Follow-on Offering
Intellia Therapeutics, a Biotech company based in 40 Erie Street, Cambridge, MA 02139, has raised $350M in Follow-on Offering at a $4.5B valuation led by Atlas Venture, Novartis Venture Fund, Venrock, Lilly Asia Ventures.
uniQure raises $345M Public Offering
uniQure raises $345M in Public Offering. Gene therapy company developing AMT-130 for Huntington's disease treatment...
Showing 9 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.